229 related articles for article (PubMed ID: 32675080)
1. Multitracer model for staging cortical amyloid deposition using PET imaging.
Collij LE; Heeman F; Salvadó G; Ingala S; Altomare D; de Wilde A; Konijnenberg E; van Buchem M; Yaqub M; Markiewicz P; Golla SSV; Wottschel V; Wink AM; Visser PJ; Teunissen CE; Lammertsma AA; Scheltens P; van der Flier WM; Boellaard R; van Berckel BNM; Molinuevo JL; Gispert JD; Schmidt ME; Barkhof F; Lopes Alves I; ;
Neurology; 2020 Sep; 95(11):e1538-e1553. PubMed ID: 32675080
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal validity of PET-based staging of regional amyloid deposition.
Jelistratova I; Teipel SJ; Grothe MJ
Hum Brain Mapp; 2020 Oct; 41(15):4219-4231. PubMed ID: 32648624
[TBL] [Abstract][Full Text] [Related]
3. In vivo staging of regional amyloid deposition.
Grothe MJ; Barthel H; Sepulcre J; Dyrba M; Sabri O; Teipel SJ;
Neurology; 2017 Nov; 89(20):2031-2038. PubMed ID: 29046362
[TBL] [Abstract][Full Text] [Related]
4. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
5. The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment.
Kim HJ; Oh JS; Lim JS; Lee S; Jo S; Chung EN; Shim WH; Oh M; Kim JS; Roh JH; Lee JH;
Alzheimers Res Ther; 2022 Jul; 14(1):93. PubMed ID: 35821150
[TBL] [Abstract][Full Text] [Related]
6. PET staging of amyloidosis using striatum.
Hanseeuw BJ; Betensky RA; Mormino EC; Schultz AP; Sepulcre J; Becker JA; Jacobs HIL; Buckley RF; LaPoint MR; Vannini P; Donovan NJ; Chhatwal JP; Marshall GA; Papp KV; Amariglio RE; Rentz DM; Sperling RA; Johnson KA; ;
Alzheimers Dement; 2018 Oct; 14(10):1281-1292. PubMed ID: 29792874
[TBL] [Abstract][Full Text] [Related]
7. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
8. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
9. Predicting future rates of tau accumulation on PET.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Vemuri P; Mielke MM; Whitwell J; Josephs K; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
Brain; 2020 Oct; 143(10):3136-3150. PubMed ID: 33094327
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O
JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858
[TBL] [Abstract][Full Text] [Related]
11. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study.
Goukasian N; Hwang KS; Romero T; Grotts J; Do TM; Groh JR; Bateman DR; Apostolova LG
BMJ Open; 2019 Dec; 9(12):e031947. PubMed ID: 31857304
[TBL] [Abstract][Full Text] [Related]
12. Performance of a [
Coomans EM; de Koning LA; Rikken RM; Verfaillie SCJ; Visser D; den Braber A; Tomassen J; van de Beek M; Collij LE; Lemstra AW; Windhorst AD; Barkhof F; Golla SSV; Visser PJ; Scheltens P; van der Flier WM; Ossenkoppele R; van Berckel BNM; van de Giessen E
Neurology; 2023 Nov; 101(19):e1850-e1862. PubMed ID: 37748892
[TBL] [Abstract][Full Text] [Related]
13. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
14. Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population.
Huang KL; Lin KJ; Hsiao IT; Kuo HC; Hsu WC; Chuang WL; Kung MP; Wey SP; Hsieh CJ; Wai YY; Yen TC; Huang CC
PLoS One; 2013; 8(3):e58974. PubMed ID: 23516589
[TBL] [Abstract][Full Text] [Related]
15. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
[TBL] [Abstract][Full Text] [Related]
16. Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study.
Sakr FA; Grothe MJ; Cavedo E; Jelistratova I; Habert MO; Dyrba M; Gonzalez-Escamilla G; Bertin H; Locatelli M; Lehericy S; Teipel S; Dubois B; Hampel H; ;
Alzheimers Res Ther; 2019 Jan; 11(1):15. PubMed ID: 30704537
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal tau PET in ageing and Alzheimer's disease.
Jack CR; Wiste HJ; Schwarz CG; Lowe VJ; Senjem ML; Vemuri P; Weigand SD; Therneau TM; Knopman DS; Gunter JL; Jones DT; Graff-Radford J; Kantarci K; Roberts RO; Mielke MM; Machulda MM; Petersen RC
Brain; 2018 May; 141(5):1517-1528. PubMed ID: 29538647
[TBL] [Abstract][Full Text] [Related]
18. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
19. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles.
Pascoal TA; Therriault J; Benedet AL; Savard M; Lussier FZ; Chamoun M; Tissot C; Qureshi MNI; Kang MS; Mathotaarachchi S; Stevenson J; Hopewell R; Massarweh G; Soucy JP; Gauthier S; Rosa-Neto P
Brain; 2020 Sep; 143(9):2818-2830. PubMed ID: 32671408
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study.
Okada Y; Kato T; Iwata K; Kimura Y; Nakamura A; Hattori H; Toyama H; Ishii K; Ishii K; Senda M; Ito K; Iwatsubo T;
Ann Nucl Med; 2020 Feb; 34(2):108-118. PubMed ID: 31749127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
